Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1

Conditions

Leukemia, Myeloid, Acute 197Leukemia 110Lymphoma 90Precursor Cell Lymphoblastic Leukemia-Lymphoma 86Burkitt Lymphoma 52Myelodysplastic Syndromes 47Lymphoma, Mantle-Cell 47Lymphoma, Large B-Cell, Diffuse 47Lymphoma, Non-Hodgkin 46Leukemia, Myelomonocytic, Acute 30Lymphoma, Follicular 29Leukemia, Monocytic, Acute 29Recurrence 25Congenital Abnormalities 25Leukemia, Erythroblastic, Acute 24Lymphoma, Large-Cell, Immunoblastic 23Leukemia, Megakaryoblastic, Acute 23Blast Crisis 21Hodgkin Disease 20Leukemia, Lymphocytic, Chronic, B-Cell 18Leukemia, Myelomonocytic, Chronic 17Leukemia, Myelogenous, Chronic, BCR-ABL Positive 17Lymphoma, B-Cell, Marginal Zone 15Anemia, Refractory, with Excess of Blasts 15Leukemia, Myeloid, Accelerated Phase 13Leukemia, Biphenotypic, Acute 13Leukemia, Myeloid, Chronic-Phase 12Dendritic Cell Sarcoma, Interdigitating 12Myeloproliferative Disorders 11Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 10

Interventions

Cyclophosphamide 14fludarabine 12fludarabine phosphate 8Melphalan 8Brentuximab Vedotin 8Whole-Body Irradiation 7Mycophenolic Acid 7Busulfan 7Rituximab 6Tacrolimus 5Lenalidomide 4Etoposide 4isatuximab 3Sirolimus 3Mesna 3Granulocyte Colony-Stimulating Factor 3Dexamethasone 3pembrolizumab 2nilotinib 2dacetuzumab 2Vincristine 2Thiotepa 2Sugars 2Stem Cell Transplantation 2Prednisone 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Ondansetron 2N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 2Methotrexate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Hematologic Diseases × Cytarabine × Clear all
NCT00528333 2015-01-07

A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML

Seagen Inc.

Phase 2 Completed
211 enrolled
Other hematologic neoplasm

Hematologic Diseases, Leukemia, Leukemia, Myeloid, Acute

NCT00594555 2008-10-31

A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia

University of Cincinnati

Phase 2 Withdrawn
20 enrolled
MyeloidOther hematologic neoplasm

Blast Crisis, Hematologic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡